EGFR and cancer: As suggested by Ibraheimet al. (2024), the possibility of lamivudineacting as a dual inhibitor, involving EGFR and VEGFR-2 (Vascular EndothelialGrowth Factor Receptor 2),) is interesting, since this synergisticeffect could enhance its efficacy by blocking multiple growth andmetastasis pathways. Furthermore, thecombined use of lamivudine with other chemotherapeutic agents, asproposed by Shetty et al. (2024), couldreduce toxicity and increase efficacy in cancers resistant to conventionaltherapies.